tbuckley/cabot-search huggingface dataset:
MA06.07 Impact of Type 2 Diabetes Mellitus and Its Metabolic Control on Prognosis of Unresectable Non-Small Cell Lung Cancer Patients
Authors: Milana Bergamino Sirvén, Aj Rullan, Maria Saigi, Inmaculada Peiró, Eduard Montanya, Ramon Palmero, Jose Carlos Ruffinelli, Arturo Navarro-Martin, Marta Domenech Viñolas, Ana Ortega Franco, Susana Padrones, Samantha Aso, Isabel Brao, Ernest Nadal, Felipe Cardenal
Journal: Journal of Thoracic Oncology (2017)
High Rate of Complete Remission (CR) and Upgraded Response with Weekly Maintenance Bortezomib Post Single Autologous Peripheral Stem Cell Transplant (PSCT) In Patients with Multiple Myeloma. Results of a Phase II Prospective Study
Authors: Firoozeh Sahebi, Amrita Krishnan, Leonardo Farol, Ji-Lian Cai, George Somlo, Leslie Popplewell, R. Spielberger, Neil Martin Kogut, Chatchada Karanes, Christopher Ruel, Paul Frankel, Eunicia Reburiano, Margret O'Donnell, Stephen Forman
Journal: Blood (2010)
Mesothelioma in the United States: A Surveillance, Epidemiology and End Results (SEER)-Medicare investigation of treatment patterns and survival.
Authors: Jennifer Lynn Beebe-Dimmer, Cecilia Yee, Tapashi Dalvi, Jon Fryzek, David Garabrant, Ann G. Schwartz, Shirish M. Gadgeel
Journal: Journal of Clinical Oncology (2015)

e18544 Background: Mesothelioma is a rare malignancy typically associated with exposure to asbestos and poor survival. The purpose of this investigation was to describe mesothelioma patient characteristics, treatment patterns and survival, both overall and according to treatment course utilizing the National Cancer Institute’s SEER-Medicare database. Methods: Patients in this study were diagnosed with malignant mesothelioma of the pleura, peritoneum or other site between 01/01/2005 and 12/31/2009 with follow-up for survival through 12/31/2010. We determined the distribution of patient and tumor characteristics at time of diagnosis, and subsequent treatment patterns (surgery, radiation and chemotherapy). Among patients treated with chemotherapy, we determined chemotherapy regimen and estimated survival by line of therapy. Results: Of the 1,625 patients considered eligible for this investigation, the median age at time of diagnosis was 78 years (age range; 66 to 103 years) and 78% were male. 30% of these patients had surgery and 45% were given chemotherapy. The median overall survival was 8 months (mos) (range 1-69 mos). The median survival of patients treated with surgery and chemotherapy (n = 249) was 14 mos and 5 mos among patients who received surgery but no chemotherapy (n = 237). Among non-surgical patients, the median survival among patients who received chemotherapy (n = 478) was 10 mos and patients who did not was 4 mos (n = 623). Among chemotherapy patients, the most commonly (68%) prescribed regimen for first line therapy was Cisplatin or Carboplatin (Ca/Ci) combined with Pemetrexed (Pe). Among those prescribed a second line therapy, retreatment with Ca/Ci + Pe was the most common treatment (33%). Conclusions: Mesothelioma patients receiving chemotherapy survive longer than patients who did not. The observational nature of this study makes it difficult to attribute differences in survival to regimen alone and may be explained by other patient-related factors.
MicroRNA Signature in Waldenstrom Macroglobulinemia
Authors: Aldo M Roccaro, Antonio Sacco, Changzhong Chen, Xavier Leleu, Judith Runnels, Feda Azab, Abdel Kareem Azab, Xiaoying Jia, Hai T Ngo, Molly R. Melhem, Nicholas Burwick, Phong Quang, Lyuba Varticovski, Carl D Novina, Barrett J. Rollins, Kenneth C. Anderson, Irene M. Ghobrial
Journal: Blood (2008)
P2.02-022 For down Staged Clinical N3 M0 Non-Small Cell Lung Cancer Patients Chemo-Radiotherapy Followed by Surgery Can Improve Survival
Authors: Jitian Zhang, Toshihiko Sato, Makoto Sonobe, Toyofumi Chen-Yoshikawa, Akihiro Aoyama, Toshi Menju, Kyoko Hijiya, Hideki Motoyama, Yukinori Matsuo, Young Kim, Hiroshi Date
Journal: Journal of Thoracic Oncology (2017)
Vascular Cell Adhesion Molecule-1 Is An Independent Prognostic Factor For Newly-Diagnosed Patients With Multiple Myeloma; Reductions Post VD and Rd In Myeloma Patients At First Relapse
Authors: Evangelos Terpos, Magdalini Migkou, Dimitrios Christoulas, Athanasios Papatheodorou, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Efstathios Kastritis, Meletios A. Dimopoulos
Journal: Blood (2013)
Phosphorylation Levels of BCR-ABL, Stat5, and CrkL Proteins in Imatinib-Resistant CML Patients as Compared to Previously Untreated CML Patients: Implication of Poor Drug Binding and Activation of Alternate Pathways.
Authors: M. Gorre, H. Kantarjian, I. Jilani, J. Cortes, A. Salvado, P. Rae, L. Alland, M. Dugan, O. Ottmann, K. Bhalla, F. Giles, M. Albitar
Journal: Blood (2005)
PUB151 The Intricate Management of the Epitheliod Haemangioendothelioma
Authors: Michail Athanasopoulos, Aspasia Antonopoulou, Domniki Iatropoulou, Davide Patrini, Nikolaos Panagiotopoulos, Efstratios Koletsis, David Lawrence
Journal: Journal of Thoracic Oncology (2017)
P110 The role of TB chemoprophylaxis in renal transplant recipients
Authors: JN Periselneris, S Mahendran, P Chowdhury, H Milburn
Journal: Thorax (2016)

<h3>Background</h3> Rates of tuberculosis infection are increased after solid organ transplant. This is associated with increased mortality and allograft loss in one third of cases. The WHO recommend testing for latent tuberculosis (LTBI) in patients receiving dialysis or preparing for solid organ transplant. BTS and ERS guidelines suggest screening for LTBI where tuberculosis incidence rates are high or in patients with risk factors for developing tuberculosis in low incidence areas. They go on to propose chemoprophylaxis with isoniazid or three months of rifampicin and isoniazid, with above 60% effectiveness at preventing subsequent tuberculosis. Guidelines at a large renal transplant centre advocate isoniazid prophylaxis for 6 months post transplant in all patients of Indo-Asian or African heritage as well as anyone who is from a country with TB incidence rates above 40/100,000 who have been in the UK for less than 5 years. <h3>Methods</h3> All patients who underwent renal transplantation between January 2011 and December 2014 were assessed to see if tuberculosis prophylaxis was prescribed as per guidelines. Cases of subsequent TB were then identified. <h3>Results</h3> 912 patients underwent renal transplant during this time. 243 (26.6%) received isoniazid prophylaxis, with 88% adherence to trust guidelines. 42 (4.6%) patients who should have received prophylaxis did not. During this time one patient developed tuberculosis post transplant. This individual should have received isoniazid according to guidelines, but did not. Another patient from sub-Saharan Africa was discovered to have abdominal tuberculosis when on the operating table prior to transplant. <h3>Discussion</h3> We are not aware of any LTBI screening programme amongst renal transplant units in the UK currently. Many use prophylactic isoniazid in a similar manner to our trust. Pre-emptive screening with interferon gamma release assays costs approximately £60 per test, 6 months of isoniazid £560 and 3 months of rifampicin and isoniazid costs £185. Whilst screening may reduce overall costs and may identify patients earlier, protocol based isoniazid prophylaxis is effective in preventing active tuberculosis. <h3>Conclusion</h3> While Isoniazid prophylaxis was effective in prevention of subsequent tuberculosis, screening prior to transplantation should have identified both patients who developed TB.
P198 Anchoring copd screening to drug services in heroin and crack smokers to improve diagnosis
Authors: R Peat, J Furlong, T Byrne, R Young, A Kangombe, T Elkin, S Renwick, D Russell, S Oelbaum, H Burhan, PP Walker
Journal: Thorax (2016)

COPD is associated with social deprivation which can reinforce health inequality, especially in difficult to access groups. Heroin and crack smoking is associated with early onset severe COPD but this population engages poorly with non-emergency medical services although they engage effectively with specialist drug services. As such, despite an expansion in community spirometry provision, different models of care may be needed to optimise COPD diagnosis and management. In order to access this group Liverpool Clinical Commissioning Group (CCG) funded a COPD screening programme where all current and former heroin and crack smokers using local drug services were offered spirometry at drug key worker appointments where they collected their opiate substitute prescription. If willing they also completed MRC, CAT, a record of cigarette and drug exposure and had oxygen saturations measured. They also provided feedback about the programme Eight hundred and seven (807) out of the population of 1100 participated which represents 73% of the client group. Airflow obstruction consistent with COPD was present in 379 (47%) with a further 50 (6%) having reversible airflow obstruction consistent with asthma. Of those with COPD, 154 (41%) had mild, 144 (38%) moderate and 81 (21%) severe or very severe COPD. Mean FEV1 was 2.93L (0.93), mean CAT was 19.5 (10.5) and mean MRC was 2.64 (1.29). Of the 379 with COPD, only a minority (41%) were diagnosed, a third of people were prescribed no inhaler therapy and, when prescribed, treatment was typically sub-optimal. Amongst those with COPD, 337 (90%) were current cigarette smokers while 93 (25%) and 105 (28%) still smoked crack and heroin respectively. When asked to feedback 96% of respondents were happy with the process and 93% would be willing to attend future COPD appointments at drug centres. Anchoring spirometry to key worker appointments in heroin and crack smokers was popular amongst service users and a majority completed spirometry. Airway disease was present in a majority with 47% having mostly undiagnosed but symptomatic COPD with significant scope to improve treatment. This model of screening and treatment improved healthcare access and could be used in other hard to reach groups, such as the homeless.
P2.05-001 α7-nAchR Agonist GTS-21 Reduces Radiation-Induced Lung Injury by Inhibiting HMGB1/TLR-4/NF-κB Pathway
Authors: Zijie Mei, Jing Chen, Yacheng Wang, Ye Yao, Xin Li, Chunxu Yang, Shimin Zhang, Conghua Xie
Journal: Journal of Thoracic Oncology (2017)
P2.03a-038 Phase III Trial of Pemetrexed/Carboplatin vs Pemetrexed Only in Chemo-Naïve Elderly Non-SQCC NSCLC Patients Aged ≥ 70
Authors: Dae Ho Lee, Seyoung Seo, Eun Kyung Cho, Jin Seok Ahn, Dong-Wan Kim, Byoung Chul Cho, Ki Hyeong Lee, Sang-We Kim
Journal: Journal of Thoracic Oncology (2017)
Ligation of CD44 by A3D8 Monoclonal Antibody Induces Terminal Differentiation of THP-1 Leukemia Cells by Promoting Cross-Talk between Extracellular Signal-Regulated Kinase and Phosphoinositide-3 Kinase/Akt Signaling Pathway.
Authors: Yoo-Hong Min, Ji Yeon Kim, Hoi Kyung Jeung, Seung Tae Lee, June-Won Cheong
Journal: Blood (2004)
S107 Genotype-phenotype associations in pulmonary arterial hypertension caused by BMPR2 and EIF2AK4 variants
Authors: C Hadinnapola, M Haimel, M Bleda, H Bogaard, G Coghlan, P Corris, S Gibbs, D Kiely, A Lawrie, A Peacock, J Pepke-Zaba, L Southgate, M Toshner, R Trembath, A Vonk Noordegraaf, J Wharton, M Wilkins, SJ Wort, S Graf, NM Morrell
Journal: Thorax (2016)

<h3>Introduction</h3> Idiopathic pulmonary arterial hypertension (IPAH) is a rare and incurable disease. Causal mutations in <i>BMPR2</i> are found in 17% of patients. Pulmonary veno-occlusive disease (PVOD) and pulmonary capillary haemangiomatosis (PCH) are rarer forms of pulmonary hypertension and have a worse prognosis. Biallelic mutations in <i>EIF2AK4</i> have been described in PVOD and PCH. We hypothesised that mutations in these genes are associated with specific phenotypes or endotypes. <h3>Methods</h3> Whole genome sequencing was performed on genomic DNA from PAH patients recruited to the NIHR BRIDGE Study (n = 679). Rare (absent from BRIDGE control cohorts [n = 5906] and minor allele frequency &lt; 0.0001 in the ExAC database [http://exac.broadinstitute.org]) and predicted deleterious (CADD score &gt;15 and Polyphen not benign) variants were selected for association testing with phenotypic and metabolomic data. Plasma samples from 288 patients were sent to Metabolon (USA) for a high-throughput metabolomic screen. <h3>Results</h3> Mutations in <i>BMPR2</i> (82 single nucleotide variants and 13 deletions) were identified in 14% of PAH patients. Unexpectedly, 22 rare and predicted deleterious <i>EIF2AK4</i> variants were found in 17 patients with IPAH. Biallelic <i>EIF2AK4</i> variants were found in 1% of patients (5 homozygous variant carriers and 4 potential compound heterozygotes). Additionally, there were 8 heterozygous<i> EIF2AK4 </i>variant carriers in the cohort (1%), suggesting a 3-fold over-representation of heterozygous <i>EIF2AK4</i> variants compared to ExAC (p = 0.005). <i>BMPR2</i> mutation carriers presented at a younger age and with more severe pulmonary haemodynamics compared to those without identified variants in the known PAH genes. Biallelic <i>EIF2AK4</i> variant carriers had a significantly reduced transfer coefficient for carbon monoxide compared to patients with <i>BMPR2</i> mutations or no identified variants. Heterozygous <i>EIF2AK4</i> variant carriers were similar to patients with no identified variants. There were no differences between groups in functional class or walk test distances assessed longitudinally. <i>BMPR2</i> and <i>EIF2AK4</i> genotype did not influence the plasma metabolome. <h3>Discussion</h3> Biallelic <i>EIF2AK4</i> variants are the second most common genetic defect in patients with apparent IPAH, after <i>BMPR2</i>. Variants in both genes are associated with characteristic phenotypes. Additional, non-coding variants may be present in heterozygous <i>EIF2AK4</i> variant carriers. These findings have important implications for the clinical and molecular classification of PAH.
P2.06-015 The NICE Salvage Study: A Phase II Trial of Weekly Nab-Paclitaxel in the Salvage Setting for Advanced Non-Small Cell Lung Cancer
Authors: Takashi Niwa, Hiroshige Yoshioka, Akito Hata, Koichi Azuma, Manabu Tajima, Mitsunori Morita, Yoshihito Kogure, Hiroaki Akamatsu, Tadashi Ishida, Nobuyuki Katakami, Tomoaki Hoshino, Mitsuhiro Takenoyama, Kazuhisa Takahashi, Hiroyasu Kaneda, Hiromi Tomioka, Hideo Saka, Masahiko Ando, Nobuyuki Yamamoto
Journal: Journal of Thoracic Oncology (2017)
PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)
Authors: Gilberto De Castro, Daniel Shao-Weng Tan, Lucio Crinò, Yi Long Wu, Luis Paz-Ares, Jürgen Wolf, Sarayut Geater, Sergey Orlov, Diego Cortinovis, Chong-Jen Yu, Maximilian Hochmair, Alexis Cortot, Chun-Ming Tsai, Denis Moro-Sibilot, Rosario García Campelo, Fabrice Branle, Paramita Sen, Tracey Mcculloch, Jean-Charles Soria
Journal: Journal of Thoracic Oncology (2017)
Up-Regulation of Prok-2 in Granulocytes Is Present BOTH in MGUS and MM
Authors: Alessandra Romano, Vittorio Simeon, Piera La Cava, Nunziatina Laura Parrinello, Alessia La Fauci, Calogero Vetro, Daniele Tibullo, Cesarina Giallongo, Maide Cavalli, Annalisa Chiarenza, Concetta Conticello, Pellegrino Musto, Francesco Di Raimondo
Journal: Blood (2014)
OA07.03 Prognostic Significance of Micrometastases in Mediastinal Lymph Nodes of Patients With Radically Resected Non-Small Cell Lung Cancer
Authors: Paweł Gwóźdź, Monika Pasieka-Lis, Katarzyna Kołodziej, Juliusz Pankowski, Marcin Zieliński
Journal: Journal of Thoracic Oncology (2017)
OA14.02 Nursing and Allied Healthcare Practitioner Driven Initiative to Develop an Integrated Educational and Assessment Program for Immunotherapy
Authors: Marianne Davies, Lisa Barbarotta, Rebecca Abramovitz, Lauren Cardone, Felicia Corolla, Michelle Randall-Doran, Monica Fradkin, Stephanie Kulakowski, Kelly Guttmann, Susan Okon, Laura Tuttle, Emily Duffield
Journal: Journal of Thoracic Oncology (2017)
P1.03-067 Validation of the IASLC 8th Edition (8E) TNM Classification for Non-Small Cell Lung Cancer by the Quality of Surgical Resection in a US Cohort
Authors: Matthew Smeltzer, Nicholas Faris, Carrie Fehnel, Cheryl Houston-Harris, Meredith Ray, Yu-Sheng Lee, Meghan Meadows, Edward Robbins, Sam Signore, Chris Mutrie, Raymond Osarogiagbon
Journal: Journal of Thoracic Oncology (2017)
Methylation of the RIZ1 Gene In Myelodysplastic Syndrome and Acute Myeloid Leukemia
Authors: Naoki Mori, Kentaro Yoshinaga, Mari Ohwashi, Toshiaki Kondoh, Hanae Shimura, Yan-Hua Wang, Kenjiro Mitsuhashi, Masayuki Shiseki, Michiko Okada, Toshiko Motoji
Journal: Blood (2010)
P1.08-059 Timing of Surgery after Induction Chemoradiation Therapy for Locally Advanced NSCLC
Authors: Huseyin Melek, Adalet Demir, Gamze Cetinkaya, Berker Ozkan, Sureyya Sarıhan, Mehmet Erol, Ahmet Sami Bayram, Alper Toker, Cengiz Gebitekin
Journal: Journal of Thoracic Oncology (2017)
The Role of Serial Testing for Heparin/PF4 Antibodies in Evolving HITT: A Unique Phenomenon of Delayed Seroconversion with Thrombosis.
Authors: Indu Sabnani, Marc Cohen, David A. Baran, Patricia Tsang, Luis H. Arroyo, Margarita Camacho, Mark J. Zucker
Journal: Blood (2007)
Granulocyte Colony-Stimulating Factor and Acute Myocardial Infarction
Authors: Jaewon Oh, Dae Hyun Kim, Hyunseok Kang
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I/II Study of Tipifarnib and Bortezomib in the Treatment of Poor Risk Adult Acute Myeloid Leukemia
Authors: Stefania Paolini, Emanuela Ottaviani, Barbara Lama, Federica Salmi, Cristina Clissa, Antonio Curti, Carlo Finelli, Panagiota Giannoulia, Ilaria Iacobucci, Claudio Laterza, Cristina Papayannidis, Sarah Parisi, Pier Paolo Piccaluga, Nicola Vianelli, Giuseppe Saglio, Renato Fanin, Fortunato Morabito, Alfonso Zaccaria, Francesco Lauria, Dino Amadori, Michele Baccarani, Giovanni Martinelli
Journal: Blood (2008)
OA10.05 EGFR Gene Mutations Affect Tumor-Infiltrating Stromal Cell Components in Early-Stage Lung Adenocarcinoma
Authors: Toshiyuki Shima, Takao Shigenobu, Masayuki Shimoda, Takashi Ohtsuka, Hisao Asamura, Yae Kanai
Journal: Journal of Thoracic Oncology (2017)
Screening for Retrovirus Genomes in Childhood Acute Lymphoblastic Leukemia
Authors: Abigail Morales-Sánchez, Juan Manuel Mejia-Arangure, Roberto Bernáldez-Ríos, Francisco Javier Álvarez-Rodríguez, Vilma Carolina Bekker-Méndez, Arturo Fajardo-Gutiérrez, Elisa Dorantes-Acosta, David Aldebarán Duarte-Rodríguez, José de Diego Flores-Chapa, Janet Flores-Lujano, Elva Jiménez-Hernández, Aurora Medina-Sanson, José Gabriel Peñaloza-González, María del Carmen Rodríguez-Zepeda, José-Refugio Torres Nava, Martha Margarita Velázquez-Aviña, Raquel Amador-Sánchez, Martha Alvarado-Ibarra, Nancy Reyes-Zepeda, Victoria Bolea-Murga, Rosa Martha Espinosa-Elizondo, Ezequiel M Fuentes-Pananá
Journal: Blood (2012)
Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia.
Authors: Franck Morschhauser, Guillaume Cartron, Thierry Lamy, Noel-Jean Milpied, Catherine Thieblemont, Hervé Tilly, Martin Weisser, Joe Birkett, Gilles Andre Salles
Journal: Blood (2009)
P3.05-005 Geriatric Assessment and Functional Decline in Older Patients with Lung Cancer
Authors: Lore Decoster, Cindy Kenis, Denis Schallier, Johan Vansteenkiste, Kristiaan Nackaerts, Leen Vanacker, Nathalie Vande Walle, Johan Flamaing, Jeanpierre Lobelle, Koen Milisen, Jacques De Grève, Hans Wildiers
Journal: Journal of Thoracic Oncology (2017)
Tumor Targeting, Dosimetry and Clinical Response Data for Lymphorad-131 (LR131; Iodine I-131 Labeled B-Lymphocyte Stimulator) in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma.
Authors: Andrew Belch, Alexander McEwan*, Joanne Hewitt*, Terence Riauka, Michael Stabin*, Aaron Brill*, Gilles Gallant, Lara Blake*, Jerry Klein
Journal: Blood (2004)
Addition of Rituximab to Fludarabine Improves Progression Free Survival in Untreated ZAP-70 Negative Chronic Lymphocytic Leukemia (CLL).
Authors: Maria Ilaria Del Principe, Giovanni Del Poeta, Luca Maurillo, Adriano Venditti, Francesco Buccisano, Elisabetta Abruzzese, Maria Irno Consalvo, Daniela Piccioni, Valter Gattei, Francesco Lo Coco, Sergio Amadori
Journal: Blood (2004)
Long Term Followup and Patterns of Failure in Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Treated On Studies Combining a Hypomethylating Agent and the Histone Deacetylase Inhibitor (HDACi) Valproic Acid.
Authors: Tapan Kadia, Zeev Estrov, Farhad Ravandi, Charles Asa Koller, Gautam Borthakur, Elias Jabbour, Stefan Faderl, Sherry Pierce, Jorge Cortes, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2009)
Pulmonary Complications Due to Iduronidase Deficiency (Hurler Syndrome) Linked to Active Pro-Inflammatory Status.
Authors: Angela Panoskaltsis-Mortari, Andrew Price, Kevin Tram, Melinda Berthold, Ron McElmurry, Jakub Tolar, Paul Orchard, Charlie Peters, Lorne Clarke, Bruce R. Blazar
Journal: Blood (2004)
Characteristics of Immune Reconstitution by Mixed Umbilical Cord Blood Transplantation In Mice: Predominant Engraftment of Major Histocompatibility Complex (MHC)-Matched Umbilical Cord Blood Stem Cell In Recipients' Bone Marrow.
Authors: Akira Nakano, Hideaki Sato, Ayumi Wakayama, Nobukata Shinohara, Kyoko Ito, Ikuo Kashiwakura, Koichi Ito
Journal: Blood (2010)